{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT00739830"], "org_study_id": ["8669-007"], "secondary_id": ["AP23573-07-205"], "nct_id": ["NCT00739830"], "brief_title": ["Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)"], "official_title": ["A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma"], "lead_sponsor": [], "source": ["Merck Sharp & Dohme LLC"], "has_dmc": ["No"], "textblock": ["The purpose of this study is to compare progression-free survival (PFS) of patients with\r\n      advanced, recurrent or metastatic endometrial cancer who have received one, but not more than\r\n      two, prior lines of chemotherapy either as adjuvant therapy or treatment for advanced\r\n      disease, and then when treated with ridaforolimus or the investigators' choice of progestin\r\n      or chemotherapy."], "overall_status": ["Completed"], "start_date": ["August 2008"], "type": ["Actual", "Actual", "Actual", "Estimate", "Estimate"], "completion_date": ["July 2012"], "primary_completion_date": ["February 2011"], "phase": ["Phase 2"], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": ["Randomized"], "intervention_model": ["Single Group Assignment"], "primary_purpose": ["Treatment"], "masking": ["None (Open Label)"], "measure": ["Progression-free survival (PFS)", "The proportion of patients progression free at 16 weeks as assessed using modified RECIST guidelines.", "The proportion of patients progression free at 26 weeks as assessed using modified RECIST guidelines", "Overall survival", "Best target lesion response, defined as best change in sum of the target lesions from baseline to disease progression", "Safety and tolerability"], "time_frame": ["From randomization up to 30 months", "From randomization to Week 16", "From randomization to Week 26", "From randomization up to 30 months", "From randomization up to 30 months", "From randomization up to 30 days after discontinuation of treatment"], "number_of_arms": [2.0], "enrollment": [130.0], "condition": ["Endometrial Cancer"], "arm_group_label": [1.0, 2.0, 1.0, 2.0, 2.0], "arm_group_type": ["Experimental", "Active Comparator"], "description": ["40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus", "Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator", "40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus", "oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)", "Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["ridaforolimus", "medroxyprogesterone acetate tablets OR megestrol acetate", "chemotherapy"], "other_name": ["deforolimus, AP23573, MK-8669; ridaforolimus was also known as deforolimus until May 2009"], "criteria": [], "gender": ["Female"], "minimum_age": ["18 Years"], "maximum_age": [], "healthy_volunteers": ["No"], "country": ["United States"], "citation": ["Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. J Clin Oncol. 2015 Nov 1;33(31):3576-82. doi: 10.1200/JCO.2014.58.8871. Epub 2015 Jun 15."], "PMID": [26077241.0], "verification_date": ["June 2015"], "study_first_submitted": ["August 20, 2008"], "study_first_submitted_qc": ["August 20, 2008"], "study_first_posted": ["August 22, 2008"], "last_update_submitted": ["June 30, 2015"], "last_update_submitted_qc": ["June 30, 2015"], "last_update_posted": ["July 1, 2015"], "responsible_party_type": ["Sponsor"], "mesh_term": ["Endometrial Neoplasms", "Medroxyprogesterone"]}